{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-267965","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2022-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.132362+00:00","generated_at":"2026-06-23T01:22:16.957112+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cullinan Oncology increases ownership in MICA subsidiary to 92% for $30.7M","bullets":["Purchased 14.97M shares from Avalon Ventures and Bregua Corp at $2.05/share, totaling $30.7M.","Ownership in MICA (holder of CLN-619 rights) increased from 54% to 92%.","MICA holds worldwide rights to CLN-619, a monoclonal antibody targeting MICA/MICB pathway.","Phase I trial of CLN-619 (monotherapy + combo with checkpoint inhibitor) on track for initial data in mid-2023.","Myeloma Investment Fund (MMRF) retained its existing ownership stake in MICA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-267965","json":"https://secwatch.observer/filing/0001193125-22-267965.json","markdown":"https://secwatch.observer/filing/0001193125-22-267965.md","text":"https://secwatch.observer/filing/0001193125-22-267965.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522267965/0001193125-22-267965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522267965/d390289d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:22:16.957112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}